Baseline patient characteristics
| Characteristics (N = 55) . | . |
|---|---|
| Median age (range), y | 65 (25-82) |
| Sex | |
| Female | 30/55 (55%) |
| Male | 25/55 (45%) |
| Race | |
| Asian | 2/55 (4%) |
| Black | 6/55 (11%) |
| White | 42/55 (76%) |
| Unknown | 5/55 (9%) |
| Ethnicity | |
| Hispanic | 5/55 (9%) |
| Stage | |
| I | 1/55 (2%) |
| II | 4/55 (7%) |
| III | 13/55 (24%) |
| IV | 37/55 (67%) |
| ECOG performance status | |
| 0-1 | 50/55 (91%) |
| 2 | 5/55 (9%) |
| IPI | |
| 0-1 (low) | 5/55 (9%) |
| 2 (low-intermediate) | 12/55 (22%) |
| 3 (high-intermediate) | 22/55 (40%) |
| 4-5 (high) | 16/55 (29%) |
| CNS-IPI | |
| 2-3 (intermediate) | 28/55 (51%) |
| 4-6 (high) | 22/55 (40%) |
| DEL | 32/55 (58%) |
| GCB | 10/32 (31%) |
| Non-GCB∗ | 22/32 (69%) |
| MYC and BCL2 or BCL6 rearrangements† | 0/27 (0%) |
| MYC rearrangement alone | 3/32 (9%) |
| DHL‡ | 23/55 (42%) |
| GCB | 20/23 (87%) |
| Non-GCB | 3/23 (13%) |
| MYC and BCL2 rearrangements | 22/23 (96%) |
| MYC and BCL6 rearrangements | 1/23 (4%) |
| Characteristics (N = 55) . | . |
|---|---|
| Median age (range), y | 65 (25-82) |
| Sex | |
| Female | 30/55 (55%) |
| Male | 25/55 (45%) |
| Race | |
| Asian | 2/55 (4%) |
| Black | 6/55 (11%) |
| White | 42/55 (76%) |
| Unknown | 5/55 (9%) |
| Ethnicity | |
| Hispanic | 5/55 (9%) |
| Stage | |
| I | 1/55 (2%) |
| II | 4/55 (7%) |
| III | 13/55 (24%) |
| IV | 37/55 (67%) |
| ECOG performance status | |
| 0-1 | 50/55 (91%) |
| 2 | 5/55 (9%) |
| IPI | |
| 0-1 (low) | 5/55 (9%) |
| 2 (low-intermediate) | 12/55 (22%) |
| 3 (high-intermediate) | 22/55 (40%) |
| 4-5 (high) | 16/55 (29%) |
| CNS-IPI | |
| 2-3 (intermediate) | 28/55 (51%) |
| 4-6 (high) | 22/55 (40%) |
| DEL | 32/55 (58%) |
| GCB | 10/32 (31%) |
| Non-GCB∗ | 22/32 (69%) |
| MYC and BCL2 or BCL6 rearrangements† | 0/27 (0%) |
| MYC rearrangement alone | 3/32 (9%) |
| DHL‡ | 23/55 (42%) |
| GCB | 20/23 (87%) |
| Non-GCB | 3/23 (13%) |
| MYC and BCL2 rearrangements | 22/23 (96%) |
| MYC and BCL6 rearrangements | 1/23 (4%) |
ECOG, Eastern Cooperative Oncology Group.
Of the patients with non-GCB DEL, 1 patient had Richter transformation, and another had Epstein-Barr virus-positive DLBCL.
There were 5 patients with DEL who did not have MYC and BCL2 FISH testing available.
Three patients with DHL had transformed follicular lymphoma.